Molecular Formula: C₁₈₁H₂₉₁N₅₅O₅₄S
Molecular Weight: 4130.6 g/mol
Sequence: Modified GLP-1(7-36) with therapeutic enhancements
Purity: >99%
Vial Size: 5mg
Storage: -20°C, protect from light
Product Overview
GLP-1-T represents next-generation glucagon-like peptide-1 therapeutic technology designed for comprehensive metabolic, cardiovascular, and neurological research applications. This advanced synthetic analog features enhanced DPP-4 resistance, extended half-life, and optimized receptor binding affinity compared to native GLP-1. Unlike natural GLP-1 with its 2-minute plasma degradation, GLP-1-T provides sustained receptor activation enabling detailed investigation of incretin pathways across diverse physiological systems.
Revolutionary Incretin Mechanism
GLP-1-T functions as a highly selective GLP-1 receptor agonist with modifications at critical amino acid positions to prevent enzymatic degradation while maintaining physiological activity. The peptide activates G protein-coupled receptor pathways, triggering glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite regulation. Enhanced stability through strategic amino acid substitutions provides researchers with extended experimental windows for mechanistic investigations.
Primary Research Applications
Diabetes & Metabolic Research
Clinical validation demonstrates superior glucose-lowering efficacy through sustained insulin stimulation from pancreatic β-cells. Studies show significant HbA1c reductions without hypoglycemia risk, enhanced β-cell proliferation while reducing apoptosis. Research applications include type 2 diabetes mechanism studies, islet preservation investigations, and metabolic homeostasis research.
Obesity & Weight Management Studies
Research reveals substantial weight loss effects through central appetite suppression and delayed gastric emptying. GLP-1-T activates hypothalamic receptors, reducing food intake and promoting sustained satiety. Studies demonstrate 15-20% body weight reductions, positioning it as powerful tool for obesity mechanism investigations and energy expenditure research.
Cardiovascular Protection Research
Clinical trials confirm significant cardiovascular benefits beyond metabolic effects. GLP-1-T reduces major adverse cardiovascular events through improved endothelial function, blood pressure reduction, enhanced myocardial contractility, and cardioprotective effects during ischemic events through direct cardiac receptor activation.
Neuroprotection & Cognitive Studies
Emerging research demonstrates GLP-1-T's ability to cross blood-brain barriers and activate CNS receptors. Studies show neuroprotective effects in neurodegenerative disease models through reduced inflammation, enhanced neuronal survival, and improved cognitive function. Applications include hippocampal neurogenesis and synaptic plasticity research.
Renal Protection Research
Studies demonstrate significant nephroprotective effects independent of glucose control. Research shows reduced albuminuria, preserved glomerular filtration rate, and decreased chronic kidney disease progression through reduced renal inflammation and improved endothelial function in kidney vasculature.
Mechanism of Action
Glucose Homeostasis: Enhanced insulin secretion with sustained glucagon suppression
Gastric Motility: Prolonged emptying delay and enhanced satiety signaling
Cardiovascular Benefits: Improved endothelial function and reduced inflammation
Neuroprotection: CNS penetration with enhanced survival pathway activation
Renal Protection: Direct nephroprotective mechanisms and albuminuria reduction
Weight Management: Central appetite suppression and metabolic optimization
Research Advantages
Extended Half-Life: Hours vs. minutes compared to native GLP-1
DPP-4 Resistance: Strategic amino acid modifications prevent enzymatic degradation
Enhanced Stability: Sustained receptor activation for extended experimental protocols
Multi-System Effects: Pancreatic, cardiovascular, neural, renal applications
Glucose-Dependent Action: No hypoglycemia risk in normoglycemic conditions
Clinical Foundation: Extensive validation in therapeutic development programs
Improved Bioavailability: Enhanced tissue penetration and receptor binding
Quality Specifications
Every GLP-1-T batch undergoes comprehensive quality control:
HPLC-MS purity analysis confirming >99% purity
Amino acid sequence verification and modification confirmation
DPP-4 resistance validation testing
Receptor binding affinity assessment
Endotoxin testing (<0.1 EU/mg)
Bioactivity assays using GLP-1 receptor cell lines
Certificate of Analysis provided with shipment
Storage & Reconstitution
Store lyophilized powder at -20°C in sealed vials. Protect from light and humidity. Reconstitute with bacteriostatic water immediately before use. Once reconstituted, use within 24 hours or store at -80°C for short-term applications. Avoid repeated freeze-thaw cycles to maintain receptor binding affinity and therapeutic potency.
Research Protocol Applications
Advanced diabetes mechanism studies and β-cell preservation research
Obesity pathway investigations and appetite regulation studies
Cardiovascular protection and MACE prevention research
Neuroprotection and cognitive enhancement investigations
Chronic kidney disease progression and protection studies
Anti-inflammatory pathway and metabolic syndrome research
Clinical translation and therapeutic optimization studies
Combination therapy development and mechanism investigations
Clinical Translation Potential
GLP-1-T research benefits from extensive therapeutic development validation with proven mechanisms in glucose homeostasis, weight management, and cardiovascular protection. The peptide's enhanced stability profile and multi-system benefits provide robust foundation for investigating novel therapeutic applications in metabolic disorders, neurodegenerative diseases, and age-related conditions.
Research Use Only: Not for human or veterinary therapeutic applications. Handle according to laboratory safety protocols and institutional research guidelines.
GLP-1-T 5mg
Typical research protocols: 1-2mg weekly for extended studies
Reconstitute with sterile bacteriostatic water
Administration methods: Subcutaneous injection or cell culture applications
Monitor for metabolic responses and receptor-mediated effects
Regular glucose and cardiovascular marker monitoring during protocols
Follow institutional guidelines for incretin peptide research procedures